789 related articles for article (PubMed ID: 25633908)
21. VivaScope® 1500 and 3000 systems for detecting and monitoring skin lesions: a systematic review and economic evaluation.
Edwards SJ; Mavranezouli I; Osei-Assibey G; Marceniuk G; Wakefield V; Karner C
Health Technol Assess; 2016 Jul; 20(58):1-260. PubMed ID: 27483991
[TBL] [Abstract][Full Text] [Related]
22. Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence.
Llewellyn A; Faria R; Woods B; Simmonds M; Lomas J; Woolacott N; Griffin S
Pharmacoeconomics; 2016 Oct; 34(10):981-92. PubMed ID: 27278217
[TBL] [Abstract][Full Text] [Related]
23. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
Kanwal F; Gralnek IM; Martin P; Dulai GS; Farid M; Spiegel BM
Ann Intern Med; 2005 May; 142(10):821-31. PubMed ID: 15897532
[TBL] [Abstract][Full Text] [Related]
24. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome.
Snowsill T; Huxley N; Hoyle M; Jones-Hughes T; Coelho H; Cooper C; Frayling I; Hyde C
Health Technol Assess; 2014 Sep; 18(58):1-406. PubMed ID: 25244061
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Noninvasive Screening for Alcohol-Related Liver Fibrosis.
Asphaug L; Thiele M; Krag A; Melberg HO
Hepatology; 2020 Jun; 71(6):2093-2104. PubMed ID: 31595545
[TBL] [Abstract][Full Text] [Related]
26. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling.
Freeman K; Connock M; Auguste P; Taylor-Phillips S; Mistry H; Shyangdan D; Court R; Arasaradnam R; Sutcliffe P; Clarke A
Health Technol Assess; 2016 Nov; 20(83):1-288. PubMed ID: 27845027
[TBL] [Abstract][Full Text] [Related]
27. Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis.
Goodacre S; Sampson F; Stevenson M; Wailoo A; Sutton A; Thomas S; Locker T; Ryan A
Health Technol Assess; 2006 May; 10(15):1-168, iii-iv. PubMed ID: 16707072
[TBL] [Abstract][Full Text] [Related]
28. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
[TBL] [Abstract][Full Text] [Related]
29. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.
Westwood M; Corro Ramos I; Lang S; Luyendijk M; Zaim R; Stirk L; Al M; Armstrong N; Kleijnen J
Health Technol Assess; 2017 May; 21(33):1-234. PubMed ID: 28643629
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
31. The cost-effectiveness of domiciliary non-invasive ventilation in patients with end-stage chronic obstructive pulmonary disease: a systematic review and economic evaluation.
Dretzke J; Blissett D; Dave C; Mukherjee R; Price M; Bayliss S; Wu X; Jordan R; Jowett S; Turner AM; Moore D
Health Technol Assess; 2015 Oct; 19(81):1-246. PubMed ID: 26470875
[TBL] [Abstract][Full Text] [Related]
32. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis.
Ciaccio A; Cortesi PA; Bellelli G; Rota M; Conti S; Okolicsanyi S; Rota M; Cesana G; Mantovani LG; Annoni G; Strazzabosco M
Liver Int; 2017 Jul; 37(7):982-994. PubMed ID: 27943549
[TBL] [Abstract][Full Text] [Related]
33. Cost-utility analysis of nonalcoholic steatohepatitis screening.
Zhang E; Wartelle-Bladou C; Lepanto L; Lachaine J; Cloutier G; Tang A
Eur Radiol; 2015 Nov; 25(11):3282-94. PubMed ID: 25994191
[TBL] [Abstract][Full Text] [Related]
34. A systematic review and economic evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA) system and Metasin test] for detecting sentinel lymph node metastases in breast cancer.
Huxley N; Jones-Hughes T; Coelho H; Snowsill T; Cooper C; Meng Y; Hyde C; Mújica-Mota R
Health Technol Assess; 2015 Jan; 19(2):v-xxv, 1-215. PubMed ID: 25586547
[TBL] [Abstract][Full Text] [Related]
35. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan.
Veenstra DL; Sullivan SD; Lai MY; Lee CM; Tsai CM; Patel KK
Value Health; 2008; 11(2):131-8. PubMed ID: 18380625
[TBL] [Abstract][Full Text] [Related]
36. Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation.
Mowatt G; Hernández R; Castillo M; Lois N; Elders A; Fraser C; Aremu O; Amoaku W; Burr J; Lotery A; Ramsay C; Azuara-Blanco A
Health Technol Assess; 2014 Dec; 18(69):1-254. PubMed ID: 25436855
[TBL] [Abstract][Full Text] [Related]
37. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.
Jones J; Shepherd J; Baxter L; Gospodarevskaya E; Hartwell D; Harris P; Price A
Health Technol Assess; 2009 Jul; 13(35):1-172, iii. PubMed ID: 19607759
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
Wu B; Li T; Chen H; Shen J
Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
[TBL] [Abstract][Full Text] [Related]
39. Entecavir for the treatment of chronic hepatitis B infection.
Shepherd J; Gospodarevskaya E; Frampton G; Cooper K
Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026
[TBL] [Abstract][Full Text] [Related]
40. The future for diagnostic tests of acute kidney injury in critical care: evidence synthesis, care pathway analysis and research prioritisation.
Hall PS; Mitchell ED; Smith AF; Cairns DA; Messenger M; Hutchinson M; Wright J; Vinall-Collier K; Corps C; Hamilton P; Meads D; Lewington A
Health Technol Assess; 2018 May; 22(32):1-274. PubMed ID: 29862965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
